Main Menu
Donate
Sign Up

ME/CFS Related Disorders Multi-Omics Study
Using Family and Population Approaches

Study AIM

Beginning in 2016, the aim of this study was to extend the Severely ill Patient Study (SIPS) and conduct a comprehensive “Big Data” analysis on ME/CFS patients and their families. 

LEAD INVESTIGATORS
  • Fereshteh K. Jahaniani, PhD
  • Michael P. Snyder, PhD
  • Ronald W. Davis, PhD
Updates and Potential
  • Published a paper on the characteristics of immune cells in ME/CFS (read here).
  • Continuing to collect longitudinal samples from patients, their unaffected family members and healthy volunteers.
  • Functional studies such as immunostaining, western blot, and RTCPR/PCR, in progress.
  • DNA and RNA extraction for whole genome, transcriptome, and DNA methylation studies in progress.
  • Two manuscripts under preparation on ME/CFS autoantibody profiling and ME/CFS plasma proteomics and cytokine landscape, which are aimed to be published in 2023.
STUDY HYPOTHESIS AND DESCRIPTION

In 2016, Fereshteh Jahanbani collaborated with Ron Davis and Mike Snyder to launch a study with the aim of deepening our understanding of how genetic and epigenetic variations impact our health, including our susceptibility to complex diseases such as ME/CFS and related comorbidities and multimorbidities.

The study was designed with the rationale that using unaffected family members as a control group would enable researchers to identify genetic and environmental risk factors that are associated with disease development, while longitudinal multi omics profiling could help to identify biomarkers and therapeutic strategies.

OBJECTIVES

Stick figure illustration of a family.

Use blood from each patient to compare patients to healthy relatives and examine:

  • Genome
  • Gene expression
  • Metabolomics
  • Proteomics
  • Cytokines
  • Microbiome
  • Autoantibodies

By comparing patients to healthy blood relatives, we are more likely to understand what genes cause or contribute to the development of ME/CFS. This data will also be integrated with the SIPS data.

Other links you might be interested in:

Digital Fundraising Toolkit
OMF Milestones
Facebook Twitter Youtube Instagram Linkedin

OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.

2024 YEAR END REPORT

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2025 Open Medicine Foundation. All Rights Reserved.

Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
Give now from your
Donor-Advised Fund
 
Donate